Animal studies have demonstrated that increases in CYP46A1 activity by genetic or pharmacologic means can be beneficial in models of Alzheimer’s and Huntington’s diseases, Niemann-Pick disease type C, spinocerebellar ataxia, depression, glioblastoma and prion disease [4–14]. This evidence concerns the gene CYP46A1 and major depressive disorder.